

# Jane Antony

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3556376/publications.pdf>

Version: 2024-02-01

14  
papers

685  
citations

1163117

8  
h-index

1125743

13  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1002  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer's model. <i>ELife</i> , 2022, 11, .	6.0	6
2	Mesenchymal tumor cells drive adaptive resistance of <i>Trp53</i> breast tumor cells to inactivated mutant <i>Kras</i> . <i>Molecular Oncology</i> , 2022, 16, 3128-3145.	4.6	1
3	The Tabula Sapiens: A multiple-organ, single-cell transcriptomic atlas of humans. <i>Science</i> , 2022, 376, eabl4896.	12.6	289
4	Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers. <i>Cancer Gene Therapy</i> , 2021, 28, 18-26.	4.6	6
5	LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis. <i>Cell Stem Cell</i> , 2020, 27, 284-299.e8.	11.1	12
6	Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions. <i>Nature Communications</i> , 2019, 10, 3134.	12.8	9
7	Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention. <i>Physical Biology</i> , 2019, 16, 041004.	1.8	49
8	Sensitization of Cancer Cells via Non-Viral Delivery of Apoptosis Inducing Proteins Using a Cationic Bolaamphiphile. <i>Biotechnology Journal</i> , 2019, 14, 1800020.	3.5	0
9	Usp16 modulates Wnt signaling in primary tissues through Cdkn2a regulation. <i>Scientific Reports</i> , 2018, 8, 17506.	3.3	8
10	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. <i>EMBO Reports</i> , 2018, 19, .	4.5	30
11	Targeting the AXL signaling pathway in ovarian cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1263716.	0.7	9
12	The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2246-2256.	4.1	24
13	AXL-Driven EMT State as a Targetable Conduit in Cancer. <i>Cancer Research</i> , 2017, 77, 3725-3732.	0.9	136
14	The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. <i>Science Signaling</i> , 2016, 9, ra97.	3.6	105